Engineered transcription factors for therapeutic angiogenesis

Current Opinion in Molecular Therapeutics

Volumn 9, Issue 2, 2007, Pages 145-152

  Kontos, Christopher D ^a   Annex, Brian H ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

Author keywords

Angiogenesis; Endothelium; Growth factors; Ischemia; Therapeutic angiogenesis; Vascular disease

Indexed keywords

ADENOVIRUS VECTOR; TRANSCRIPTION FACTOR; VASCULOTROPIN; ZINC FINGER PROTEIN;

ANGIOGENESIS; CLINICAL TRIAL; HUMAN; ISCHEMIC HEART DISEASE; LIMB ISCHEMIA; NONHUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; REVIEW; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; CELL HYPOXIA; CLINICAL TRIALS; GENETIC ENGINEERING; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; TRANSCRIPTION FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTORS;

HARNESS;

EID: 34247364063     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Carmeliet P: Angiogenesis in health and disease. Nat Med (2003) 9(6):653-660.
2. Ferrara N, Alitalo K: Clinical applications of angiogenic growth factors and their inhibitors. Nat Med (1999) 5(12):1359-1364.
3. Freedman SB, Isner JM: Therapeutic angiogenesis for coronary artery disease. Ann Intern Med (2002) 136(1):54-71.
4. Henry TD, Annex BH, McKendall GR, Azrin MA, Lopez JJ, Giordano FJ, Shah PK, Willerson JT, Benza RL, Berman DS, Gibson CM et al: The VIVA trial: Vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation (2003) 107(10):1359-1365.
5. Rajagopalan S, Mohler ER III, Lederman RJ, Mendelsohn FO, Saucedo JF, Goldman CK, Blebea J, Macko J, Kessler PD, Rasmussen HS, Annex BH: Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: A phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation (2003) 108(16):1933- 1938.
6. 121 (AdVEGF121) versus maximum medical treatment. Gene Ther (2006) 13(21):1503-1511.
7. Lederman RJ, Mendelsohn FO, Anderson RD, Saucedo JF, Tenaglia AN, Hermiller JB, Hillegass WB, Rocha-Singh K, Moon TE, Whitehouse MJ, Annex BH: Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): A randomised trial. Lancet (2002) 359(9323):2053-2058.
8. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J: Vascular-specific growth factors and blood vessel formation. Nature (2000) 407(6801):242-248.
9. Gale NW, Yancopoulos GD: Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev (1999) 13(9):1055-1066.
10. Schofield CJ, Ratcliffe PJ: Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol (2004) 5(5):343-354.
11. Manalo DJ, Rowan A, Lavoie T, Natarajan L, Kelly BD, Ye SQ, Garcia JG, Semenza GL: Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood (2005) 105(2):659-669.
12. Jiang C, Lu H, Vincent KA, Shankara S, Belanger AJ, Cheng SH, Akita GY, Kelly RA, Goldberg MA, Gregory RJ: Gene expression profiles in human cardiac cells subjected to hypoxia or expressing a hybrid form of HIF-1α. Physiol Genomics (2002) 8(1):23-32. • A comparison of gene expression changes in response to hypoxia and treatment with an HIF-1 α hybrid transcription factor.
13. Ferrara N: Vascular endothelial growth factor: Basic science and clinical progress. Endocr Rev (2004) 25(4):581-611. •• An excellent and comprehensive review of the VEGF ligand and receptor family.
14. Carmeliet P, Ferreira V, Breier G, Pollefey S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Ebenhardt C, Declercq C et al: Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature (1996) 380(6573):435-439.
15. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS, Powell-Braxton L, Hillan KJ, Moore MW: Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature (1996) 380(6573):439-442.
16. Robinson CJ, Stringer SE: The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci (2001) 114(5):853-865.
17. Ruhrberg C, Gerhardt H, Golding M, Watson R, Ioannidou S, Fujisawa H, Betsholtz C, Shima DT: Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis. Genes Dev (2002) 16(20):2684-2698.
18. 188. Nat Med (1999) 5(5):495-502.
19. Dor Y, Djonov V, Abramovitch R, Itin A, Fishman GI, Carmeliet P, Goelman G, Keshet E: Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy. EMBO J (2002) 21(8):1939-1947.
20. Plouet J, Moro F, Bertagnolli S, Coldeboeuf N, Mazarguil H, Clamens S, Bayard F: Extracellular cleavage of the vascular endothelial growth factor 189-amino acid form by urokinase is required for its mitogenic effect. J Biol Chem (1997) 272(20):13390-13396.
21. Whitlock PR, Hackett NR, Leopold PL, Rosengart TK, Crystal RG: Adenovirus-mediated transfer of a minigene expressing multiple isoforms of VEGF is more effective at inducing angiogenesis than comparable vectors expressing individual VEGF cDNAs. Mol Ther (2004) 9(1):67-75. • A study demonstrating that simultaneous administration of multiple VEGF isoforms has a more beneficial effect than a single isoform alone in a preclinical model of hindlimb ischemia.
22. 2 zinc finger proteins. Annu Rev Biochem (2001) 70:313-340.
23. Urnov FD, Rebar EJ: Designed transcription factors as tools for therapeutics and functional genomics. Biochem Pharmacol (2002) 64(5-6):919-923.
24. Snowden AW, Zhang L, Urnov F, Dent C, Jouvenot Y, Zhong X, Rebar EJ, Jamieson AC, Zhang HS, Tan S, Case CC et al: Repression of vascular endothelial growth factor A in glioblastoma cells using engineered zinc finger transcription factors. Cancer Res (2003) 63(24):8968-8976.
25. Liu PQ, Rebar EJ, Zhang L, Liu Q, Jamieson AC, Liang Y, Qi H, Li PX, Chen B, Mendel MC, Zhong X et al: Regulation of an endogenous locus using a panel of designed zinc finger proteins targeted to accessible chromatin regions. Activation of vascular endothelial growth factor A. J Biol Chem (2001) 276(14):11323-11334. • A description of the design and development of ZFP transcription factors specific for the human VEGF-A gene.
26. Rebar EJ, Huang Y, Hickey R, Nath AK, Meoli D, Nath S, Chen B, Xu L, Liang Y, Jamieson AC, Zhang L et al: Induction of angiogenesis in a mouse model using engineered transcription factors. Nat Med (2002) 8(12):1427-1432. •• The in vitro evaluation and subsequent in vivo application of the murinespecific VEGF-ZFPs are described.
27. Dai Q, Huang J, Klitzman B, Dong C, Goldschmidt-Clermont PJ, March KL, Rokovich J, Johnstone B, Rebar EJ, Spratt SK, Case CC et al: Engineered zinc finger-activating vascular endothelial growth factor transcription factor plasmid DNA induces therapeutic angiogenesis in rabbits with hindlimb ischemia. Circulation (2004) 110(16):2467-2475. •• The first description of the use of a VEGF-ZFP transcription factor in a preclinical model of hindlimb ischemia.
28. Elson DA, Thurston G, Huang LE, Ginzinger DG, McDonald DM, Johnson RS, Arbeit JM: Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1α. Genes Dev (2001) 15(19):2520-2532.
29. Thurston G, Suri C, Smith K, McClain J, Sato TN, Yancopoulos GD, McDonald DM: Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science (1999) 286(5449):2511-2514.
30. Tan S, Guschin D, Davalos A, Lee YL, Snowden AW, Jouvenot Y, Zhang HS, Howes K, McNamara AR, Lai A, Ullman C et al: Zinc-finger protein-targeted gene regulation: Genomewide single-gene specificity. Proc Natl Acad Sci USA (2003) 100(21):11997-12002. • Description of the specificity that can be imparted with engineered ZFP transcription factors.
31. Couffinhal T, Silver M, Kearney M, Sullivan A, Witzenbichler B, Magner M, Annex B, Peters K, Isner JM: Impaired collateral vessel development associated with reduced expression of vascular endothelial growth factor in ApoE-/- mice. Circulation (1999) 99(24):3188-3198.
32. Rivard A, Silver M, Chen D, Kearney M, Magner M, Annex B, Peters K, Isner JM: Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. Am J Pathol (1999) 154(2):355- 363.
33. Rivard A, Fabre JE, Silver M, Chen D, Murohara T, Kearney M, Magner M, Asahara T, Isner JM: Age-dependent impairment of angiogenesis. Circulation (1999) 99(1):111-120.
34. Xie D, Li Y, Reed EA, Odronic SI, Kontos CD, Annex BH: An engineered vascular endothelial growth factor-activating transcription factor induces therapeutic angiogenesis in ApoE knockout mice with hindlimb ischemia. J Vasc Surg (2006) 44(1):166-175. • Demonstration that a VEGF-ZFP can enhance angiogenesis in hypercholesterolemic, ApoE-/- mice, a preclinical model with deficient angiogenesis.
35. Yu J, Lei L, Liang Y, Hinh L, Hickey RP, Huang Y, Liu D, Yeh JL, Rebar E, Case C, Spratt K et al: An engineered VEGF-activating zinc finger protein transcription factor improves blood flow and limb salvage in advanced-age mice. FASEB J (2006) 20(3):479-481.
36. Oosthuyse B, Moons L, Storkebaum E, Beck H, Nuyens D, Brusselmans K, Van Dorpe J, Hellings P, Gorselink M, Heymans S, Theilmeier G et al: Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet (2001) 28(2):131-138.
37. Price SA, Dent C, Duran-Jimenez B, Liang Y, Zhang L, Rebar EJ, Case CC, Gregory PD, Martin TJ, Spratt SK, Tomlinson DR: Gene transfer of an engineered transcription factor promoting expression of VEGF-A protects against experimental diabetic neuropathy. Diabetes (2006) 55(6):1847-1854.
38. Vincent KA, Feron O, Kelly RA: Harnessing the response to tissue hypoxia: HIF-α and therapeutic angiogenesis. Trends Cardiovasc Med (2002) 12(8):362-367.
39. Vincent KA, Shyu KG, Luo Y, Magner M, Tio RA, Jiang C, Goldberg MA, Akita GY, Gregory RJ, Isner JM: Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF-1α/VP16 hybrid transcription factor. Circulation (2000) 102(18):2255-2261. •• The first demonstration that an HIF-1 α hybrid transcription factor can improve angiogenesis in a preclinical model.
40. Yamakawa M, Liu LX, Date T, Belanger AJ, Vincent KA, Akita GY, Kuriyama T, Cheng SH, Gregory RJ, Jiang C: Hypoxia-inducible factor-1 mediates activation of cultured vascular endothelial cells by inducing multiple angiogenic factors. Circ Res (2003) 93(7):664-673.
41. Liu LX, Lu H, Luo Y, Date T, Belanger AJ, Vincent KA, Akita GY, Goldberg M, Cheng SH, Gregory RJ, Jiang C: Stabilization of vascular endothelial growth factor mRNA by hypoxia-inducible factor 1. Biochem Biophys Res Commun (2002) 291(4):908-914.
42. Shyu KG, Wang MT, Wang BW, Chang CC, Leu JG, Kuan P, Chang H: Intramyocardial injection of naked DNA encoding HIF-1α/VP16 hybrid to enhance angiogenesis in an acute myocardial infarction model in the rat. Cardiovasc Res (2002) 54(3):576-583.
43. Date T, Mochizuki S, Belanger AJ, Yamakawa M, Luo Z, Vincent KA, Cheng SH, Gregory RJ, Jiang C: Expression of constitutively stable hybrid hypoxia-inducible factor-1α protects cultured rat cardiomyocytes against simulated ischemia-reperfusion injury. Am J Physiol Cell Physiol (2005) 288(2):C314-C320.
44. Yamakawa M, Liu LX, Belanger AJ, Date T, Kuriyama T, Goldberg MA, Cheng SH, Gregory RJ, Jiang C: Expression of angiopoietins in renal epithelial and clear cell carcinoma cells: Regulation by hypoxia and participation in angiogenesis. Am J Physiol Renal Physiol (2004) 287(4):F649- F657.